Potential Advantages of Torsemide in Patients with Heart Failure: More than Just a ‘Water Pill’?
Why the study?
Does torsemide reduce serum PIP levels compared to furosemide in patients with HFpEF and type 2 diabetes?
Population
35 patients with HFpEF, type 2 diabetes mellitus, and either baseline PIP ≥110 ng/mL or PIP ≥70 ng/mL with…
Comparison
Torsemide 5 mg/day vs Furosemide 20 mg/day
Design
Editorial, randomized controlled, double-blind
Follow-up
9 months
Authors
Discussion
Loading...
Member takes
Implication
Despite theoretical anti-fibrotic advantages, a small randomized trial found no significant difference between torsemide and furosemide in reducing myocardial fibrosis biomarkers in HFpEF, emphasizing the need for larger clinical outcome trials.
Structured PICO
Does torsemide reduce serum PIP levels compared to furosemide in patients with HFpEF and type 2 diabetes?
P
Population
35 patients with HFpEF, type 2 diabetes mellitus, and either baseline PIP ≥110 ng/mL or PIP ≥70 ng/mL with left atrial enlargement
I
Intervention
Torsemide 5 mg/day
C
Comparator
Furosemide 20 mg/day
O
Outcome
Percentage change in serum C-terminal propeptide of procollagen type I (PIP) value from baseline to 9 monthssurrogate
Despite theoretical anti-fibrotic advantages, a small randomized trial found no significant difference between torsemide and furosemide in reducing myocardial fibrosis biomarkers in HFpEF, emphasizing the need for larger clinical outcome trials.
Limitations
- small sample size
- single-centre nature
- dropout of nearly one in five patients
- unjustified choice of drug dosing (5 mg torsemide vs 20 mg furosemide)
- imbalanced baseline PIP levels across study arms
- low-risk patient phenotype with minimal congestion
Cite This Study
Greene et al. (2017) studied this question.